PortfoliosLab logoPortfoliosLab logo
ENTA vs. OMER
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ENTA vs. OMER - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Enanta Pharmaceuticals, Inc. (ENTA) and Omeros Corporation (OMER). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ENTA achieves a -20.10% return, which is significantly higher than OMER's -31.06% return. Over the past 10 years, ENTA has underperformed OMER with an annualized return of -5.43%, while OMER has yielded a comparatively higher -0.03% annualized return.


ENTA

1D
-3.08%
1M
-16.61%
6M
-2.33%
YTD
-20.10%
1Y
77.22%
3Y*
-12.24%
5Y*
-21.49%
10Y*
-5.43%
ALL TIME*
-1.05%

OMER

1D
-0.75%
1M
27.59%
6M
1.28%
YTD
-31.06%
1Y
227.98%
3Y*
41.60%
5Y*
-3.97%
10Y*
-0.03%
ALL TIME*
1.78%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$1.83M$2.27M$2.92M
$16.98M$15.21M$19.60M

ENTA vs. OMER - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ENTA
Enanta Pharmaceuticals, Inc.
-20.10%174.26%-38.89%-79.77%-37.79%77.62%-31.85%-12.78%20.71%75.16%
OMER
Omeros Corporation
-31.06%73.84%202.14%44.69%-64.85%-54.99%1.38%26.48%-42.67%95.87%

Correlation

The correlation between ENTA and OMER is 0.31, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.31

Correlation (3Y)
Balances recent behavior with more history.

0.29

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.29

Correlation (10Y)
Provides a long-term view across more market conditions.

0.28

Correlation (All Time)
Calculated using the full available price history since Mar 21, 2013

0.27

Fundamentals

Market Cap

ENTA:

$366.39M

OMER:

$856.92M

EPS

ENTA:

-$2.60

OMER:

-$0.05

Total Revenue (TTM)

ENTA:

$69.21M

OMER:

$0.00

Gross Profit (TTM)

ENTA:

$33.44M

OMER:

-$10.29M

EBITDA (TTM)

ENTA:

-$61.85M

OMER:

-$110.44M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ENTA vs. OMER — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ENTA
ENTA Risk / Return Rank: 7676
Overall Rank
ENTA Sharpe Ratio Rank: 6666
Sharpe Ratio Rank
ENTA Sortino Ratio Rank: 8282
Sortino Ratio Rank
ENTA Omega Ratio Rank: 8282
Omega Ratio Rank
ENTA Calmar Ratio Rank: 7878
Calmar Ratio Rank
ENTA Martin Ratio Rank: 7373
Martin Ratio Rank

OMER
OMER Risk / Return Rank: 9090
Overall Rank
OMER Sharpe Ratio Rank: 7878
Sharpe Ratio Rank
OMER Sortino Ratio Rank: 9797
Sortino Ratio Rank
OMER Omega Ratio Rank: 9696
Omega Ratio Rank
OMER Calmar Ratio Rank: 9393
Calmar Ratio Rank
OMER Martin Ratio Rank: 8686
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ENTA vs. OMER - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Enanta Pharmaceuticals, Inc. (ENTA) and Omeros Corporation (OMER). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ENTAOMERDifference
Sharpe ratioReturn per unit of total volatility

-0.49

Sortino ratioReturn per unit of downside risk

-2.01

Omega ratioGain probability vs. loss probability

1.28

1.52

-0.24

Calmar ratioReturn relative to maximum drawdown

1.94

4.19

-2.25

Martin ratioReturn relative to average drawdown

3.44

7.55

-4.11

ENTA vs. OMER - Sharpe Ratio Comparison

The current ENTA Sharpe Ratio is 0.61, which is lower than the OMER Sharpe Ratio of 1.10. The chart below compares the historical Sharpe Ratios of ENTA and OMER, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ENTA vs. OMER - Drawdown Comparison

The maximum ENTA drawdown since its inception was -96.63%, roughly equal to the maximum OMER drawdown of -95.95%. Use the drawdown chart below to compare losses from any high point for ENTA and OMER.


Loading charts...

Drawdown Indicators


ENTAOMERDifference

Max Drawdown

Largest peak-to-trough decline

-96.63%

-95.95%

-0.68%

Max Drawdown (1Y)

Largest decline over 1 year

-34.30%

-49.52%

+15.22%

Max Drawdown (3Y)

Largest decline over 3 years

-78.51%

-75.56%

-2.95%

Max Drawdown (5Y)

Largest decline over 5 years

-95.62%

-93.37%

-2.25%

Max Drawdown (10Y)

Largest decline over 10 years

-96.63%

-95.95%

-0.68%

Current Drawdown

Current decline from peak

-90.03%

-55.64%

-34.39%

Average Drawdown

Average peak-to-trough decline

-49.66%

-48.60%

-1.06%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.35%

27.43%

-8.08%

Volatility

ENTA vs. OMER - Volatility Comparison

The current volatility for Enanta Pharmaceuticals, Inc. (ENTA) is 11.70%, while Omeros Corporation (OMER) has a volatility of 24.61%. This indicates that ENTA experiences smaller price fluctuations and is considered to be less risky than OMER based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ENTAOMERDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.70%

24.61%

-12.91%

Volatility (6M)

Calculated over the trailing 6-month period

34.43%

52.47%

-18.04%

Volatility (1Y)

Calculated over the trailing 1-year period

108.78%

188.53%

-79.75%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

73.65%

135.68%

-62.03%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

60.73%

111.33%

-50.60%

Dividends

ENTA vs. OMER - Dividend Comparison

Neither ENTA nor OMER has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ENTA vs. OMER - Financials Comparison

This section allows you to compare key financial metrics between Enanta Pharmaceuticals, Inc. and Omeros Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


ENTA and OMER have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

OMER has higher volatility (24.61%) compared to ENTA (11.70%). In terms of maximum drawdown, ENTA dropped -96.63% vs OMER's -95.95%.

OMER currently has the higher Sharpe Ratio (1.10 vs 0.61), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ENTA and OMER

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer